Expression of LAG-3 on tumor-infiltrating lymphocytes (TILs) and peripheral blood cells correlates with early recurrence and poor prognosis in patients who received anti-PD-1 ± anti-CTLA-4 regimen.49–51 Development of drugs targeting LAG-3 focuses on anti-LAG-3 monoclonal antibodies (mAbs), LAG-3-Ig fusion proteins, and bsAbs/msAbs targeting LAG-3 (Table 1 and Supplementary Table 1). Here, LAG3 is linked to neoplasm.